Your browser doesn't support javascript.
loading
[Immune-mediated inflammatory diseases in Germany : A cross-sectional analysis of comorbidities and pharmacotherapy]. / Chronische Entzündungserkrankungen in Deutschland : Eine Querschnittanalyse über Begleiterkrankungen und Arzneimitteleinsatz.
Leipe, Jan; Schmelz, Renate; Riemekasten, Gabriela; Thaçi, Diamant; Henes, Jörg; Schäkel, Knut; Pinter, Andreas; Sticherling, Michael; Wegner, Joanna; Fusco, Stefano; Linke, Miriam; Weber, Valeria; Manz, Karina C; Bartz, Holger; Roecken, Marit; Schmidt, Sandra; Hoyer, Bimba F.
Afiliação
  • Leipe J; Sektion Rheumatologie, V. Medizinische Klinik, Universitätsklinikum Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Deutschland. jan.leipe@umm.de.
  • Schmelz R; Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Deutschland.
  • Riemekasten G; Klinik für Rheumatologie und klinische Immunologie, Universitätsklinikum Schleswig-Holstein, Lübeck, Deutschland.
  • Thaçi D; Institut und Exzellenzzentrum für Entzündungsmedizin, Universität zu Lübeck, Schleswig-Holstein, Lübeck, Deutschland.
  • Henes J; Zentrum für interdisziplinäre und klinische Immunologie, Rheumatologie und autoinflammatorische Erkrankungen (INDIRA) und innere Medizin II, Universitätsklinikum Tübingen, Tübingen, Deutschland.
  • Schäkel K; Hautklinik, IZEH - Interdisziplinäres Zentrum für chronisch entzündliche Erkrankungen, Universitätsklinikum Heidelberg, Heidelberg, Deutschland.
  • Pinter A; Klinik für Dermatologie, Venerologie und Allergologie, Universtitätsklinikum Frankfurt, Frankfurt, Deutschland.
  • Sticherling M; Hautklinik, Psoriasiszentrum, Deutsches Zentrum für Immuntherapie, Universitätsklinikum Erlangen, Erlangen, Deutschland.
  • Wegner J; Hautklinik und Poliklinik, Universitätsitätsmedizin der Johannes-Gutenberg-Universität Mainz, Mainz, Deutschland.
  • Fusco S; Medizinische Klinik I, Universitätsklinikum Tübingen, Tübingen, Deutschland.
  • Linke M; Klinik für Dermatologie, Venerologie und Allergologie, Universitätsmedizin Mannheim, Mannheim, Deutschland.
  • Weber V; IGES Institut GmbH, Berlin, Deutschland.
  • Manz KC; IGES Institut GmbH, Berlin, Deutschland.
  • Bartz H; Janssen-Cilag GmbH, Neuss, Deutschland.
  • Roecken M; Janssen-Cilag GmbH, Neuss, Deutschland.
  • Schmidt S; Janssen-Cilag GmbH, Neuss, Deutschland.
  • Hoyer BF; Klinik für Innere Medizin I, Sektion Rheumatologie und klinische Immunologie, Universitätsklinikum Schleswig-Holstein, Kiel, Deutschland.
Z Rheumatol ; 83(3): 200-209, 2024 Apr.
Article em De | MEDLINE | ID: mdl-36600054
ABSTRACT

BACKGROUND:

Immune-mediated inflammatory diseases (IMID) can lead to a substantial disease burden for those affected, in particular by the concomitant occurrence of other IMIDs or in the presence of comorbidities. The care of patients with IMIDs is complex and involves various medical disciplines.

OBJECTIVE:

To describe the burden of disease and the current routine drug treatment of patients with IMID. MATERIAL AND

METHODS:

The retrospective cross-sectional analysis was based on statutory health insurance claims data from the InGef database. Prevalent patients with psoriasis (Pso), psoriatic arthritis (PsA), spondylarthritis (SpA), rheumatoid arthritis (RA), Crohn's disease (MC), ulcerative colitis (CU), or connective tissue disease were identified among 3,988,695 insured patients in 2018. The concomitant occurrence of different IMIDs and the extent to which patients with IMID are affected by other comorbidities compared to a reference population were investigated. The current routine drug treatment was described based on the use of predefined forms of treatment.

RESULTS:

In the database 188,440 patients with IMID (4.7%) were identified. Compared to the reference population the prevalence of comorbidities, such as depressive episodes and cardiovascular risk factors was higher in patients with IMID. For MC, CU, RA, and PsA disease-modifying antirheumatic drugs (DMARD) and classical systemic forms of treatment were used most commonly. In Pso, SpA, and connective tissue disease nonsteroidal anti-inflammatory drugs (NSAID) were the most frequently used treatment often in combination with other drugs.

CONCLUSION:

A considerable number of patients with IMIDs (16.9-27.5%) suffer from different diseases of the IMID group. They are frequently affected by accompanying illnesses and require interdisciplinary medical treatment.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Psoríase / Artrite Psoriásica / Espondilartrite Tipo de estudo: Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: De Revista: Z Rheumatol Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Psoríase / Artrite Psoriásica / Espondilartrite Tipo de estudo: Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: De Revista: Z Rheumatol Ano de publicação: 2024 Tipo de documento: Article